{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:08:10Z","timestamp":1789520890956,"version":"build-2803163510"},"reference-count":192,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772680"],"award-info":[{"award-number":["81772680"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bbcan.2026.189691","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:20:27Z","timestamp":1787325627000},"page":"189691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Decoding the spatiotemporal dynamics of T cell immune landscapes in glioblastoma: remodeling precision combination therapies"],"prefix":"10.1016","volume":"1881","author":[{"given":"Qingya","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarui","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bbcan.2026.189691_bb0005","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1093\/neuonc\/noaf177","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"27","author":"Wen","year":"2025","journal-title":"Neuro-Oncology"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189691_bb0010","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain malignancies in adults: a review","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.bbcan.2026.189691_bb0015","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1146\/annurev-med-042420-102102","article-title":"New approaches to glioblastoma","volume":"73","author":"Khasraw","year":"2022","journal-title":"Annu. Rev. Med."},{"issue":"23","key":"10.1016\/j.bbcan.2026.189691_bb0020","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial","volume":"314","author":"Stupp","year":"2015","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189691_bb0025","article-title":"Incorporation of immunotherapy into adult B-cell acute lymphoblastic leukemia therapy","volume":"23","author":"Haddad","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189691_bb0030","first-page":"3967","article-title":"Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma","volume":"12","author":"Pillai","year":"2022","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0035","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41698-022-00292-6","article-title":"Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations","volume":"6","author":"Zhang","year":"2022","journal-title":"npj Precis. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189691_bb0040","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bbcan.2026.189691_bb0045","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.critrevonc.2018.12.002","article-title":"PD-1\/PD-L1 immune-checkpoint inhibitors in glioblastoma: a concise review","volume":"135","author":"Caccese","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189691_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002296","article-title":"Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial","volume":"9","author":"Duerinck","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0055","first-page":"29","article-title":"Immunosuppressive mechanisms and therapeutic interventions shaping glioblastoma immunity","volume":"7","author":"Moreno-Sanchez","year":"2026","journal-title":"Nat. Can."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189691_bb0060","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/neuonc\/noy032","article-title":"CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges","volume":"20","author":"Bagley","year":"2018","journal-title":"Neuro-Oncology"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189691_bb0065","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","article-title":"The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy","volume":"20","author":"Bruni","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"6574","key":"10.1016\/j.bbcan.2026.189691_bb0070","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe6474","article-title":"Pan-cancer single-cell landscape of tumor-infiltrating T cells","volume":"374","author":"Zheng","year":"2021","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189691_bb0075","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41568-025-00832-9","article-title":"Regulatory T cells in the tumour microenvironment","volume":"25","author":"Imianowski","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2026.189691_bb0080","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.coi.2021.09.005","article-title":"The role of CD4 T cells in rejection of solid tumors","volume":"74","author":"Poncette","year":"2022","journal-title":"Curr. Opin. Immunol."},{"issue":"13","key":"10.1016\/j.bbcan.2026.189691_bb0085","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1158\/1078-0432.CCR-10-2557","article-title":"Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-\u03b2","volume":"17","author":"Lohr","year":"2011","journal-title":"Clin. Cancer Res. Offl. J. Am. Assoc. Cancer Res."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189691_bb0090","first-page":"1381","article-title":"CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival","volume":"17","author":"Yang","year":"2010","journal-title":"J. Clin. Neurosci. Offl. J. Neurosurg. Soc. Australas."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189691_bb0095","article-title":"Correction: mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies","volume":"9","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189691_bb0100","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.cell.2020.04.055","article-title":"Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes","volume":"181","author":"Friebel","year":"2020","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189691_bb0105","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","article-title":"The microenvironmental landscape of brain tumors","volume":"31","author":"Quail","year":"2017","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189691_bb0110","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-018-0135-2","article-title":"Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors","volume":"24","author":"Chongsathidkiet","year":"2018","journal-title":"Nat. Med."},{"issue":"24","key":"10.1016\/j.bbcan.2026.189691_bb0115","doi-asserted-by":"crossref","first-page":"6720","DOI":"10.1016\/j.cell.2025.09.021","article-title":"CRATER tumor niches facilitate CD8(+) T cell engagement and correspond with immunotherapy success","volume":"188","author":"Ludin","year":"2025","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0120","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1038\/s41467-025-61822-x","article-title":"Integrative multi-omics reveals a regulatory and exhausted T-cell landscape in CLL and identifies galectin-9 as an immunotherapy target","volume":"16","author":"Lla\u00f3-Cid","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0125","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12943-024-02104-w","article-title":"Phenotypic and spatial heterogeneity of CD8(+) tumour infiltrating lymphocytes","volume":"23","author":"Sun","year":"2024","journal-title":"Mol. Cancer"},{"issue":"7871","key":"10.1016\/j.bbcan.2026.189691_bb0130","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-021-03634-9","article-title":"Exploring tissue architecture using spatial transcriptomics","volume":"596","author":"Rao","year":"2021","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189691_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002640","article-title":"Understanding glioblastoma at the single-cell level: recent advances and future challenges","volume":"22","author":"Yabo","year":"2024","journal-title":"PLoS Biol."},{"issue":"6389","key":"10.1016\/j.bbcan.2026.189691_bb0140","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1126\/science.aaf2666","article-title":"An anatomic transcriptional atlas of human glioblastoma","volume":"360","author":"Puchalski","year":"2018","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189691_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189383","article-title":"Spatial heterogeneity in glioblastoma: decoding the role of perfusion","volume":"1880","author":"Saha","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189691_bb0150","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/neuonc\/noaf236","article-title":"T cell immunity in glioma and potential implications for immunotherapy: a systematic review","volume":"28","author":"Luning","year":"2026","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0155","doi-asserted-by":"crossref","first-page":"7246","DOI":"10.1038\/s41598-024-56102-5","article-title":"Hypoxia drives shared and distinct transcriptomic changes in two invasive glioma stem cell lines","volume":"14","author":"Marallano","year":"2024","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189691_bb0160","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.cell.2021.01.022","article-title":"Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis","volume":"184","author":"Mathewson","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0165","article-title":"Coordinative metabolism of glutamine carbon and nitrogen in proliferating cancer cells under hypoxia","volume":"10","author":"Wang","year":"2019","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189691_bb0170","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189691_bb0175","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.ajpath.2017.01.010","article-title":"Hypoxia-mediated mechanisms associated with antiangiogenic treatment resistance in glioblastomas","volume":"187","author":"Mahase","year":"2017","journal-title":"Am. J. Pathol."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189691_bb0180","first-page":"3810","article-title":"Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition","volume":"117","author":"Higgins","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"18","key":"10.1016\/j.bbcan.2026.189691_bb0185","article-title":"Spatiotemporal insights into glioma oncostream dynamics: unraveling formation, stability, and disassembly pathways (Adv. Sci. 18\/2024)","volume":"11","author":"Faisal","year":"2024","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0190","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1038\/s41467-022-31340-1","article-title":"Spatiotemporal analysis of glioma heterogeneity reveals COL1A1 as an actionable target to disrupt tumor progression","volume":"13","author":"Comba","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189691_bb0195","article-title":"Tumor microenvironment in glioblastoma: the central role of the hypoxic-necrotic core","volume":"639","author":"Bayona","year":"2025","journal-title":"Cancer Lett."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189691_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2023.06.017","article-title":"Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression","volume":"56","author":"Sattiraju","year":"2023","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189691_bb0205","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s11060-025-05232-5","article-title":"Tumor and immune cell distribution in the tumor core and outer part of glioblastoma, IDH wildtype","volume":"175","author":"Pedersen","year":"2025","journal-title":"J. Neuro-Oncol."},{"issue":"19","key":"10.1016\/j.bbcan.2026.189691_bb0210","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1158\/0008-5472.CAN-16-0144","article-title":"CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells","volume":"76","author":"Chang","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189691_bb0215","article-title":"Neutrophils in glioma microenvironment: from immune function to immunotherapy","volume":"15","author":"Sun","year":"2024","journal-title":"Front. Immunol."},{"issue":"21","key":"10.1016\/j.bbcan.2026.189691_bb0220","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1016\/j.cell.2023.08.043","article-title":"The local microenvironment drives activation of neutrophils in human brain tumors","volume":"186","author":"Maas","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0225","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12943-026-02570-4","article-title":"Spatiotemporal dynamics of tumor-associated neutrophils: bridging the gap between cancer progression and immunotherapy","volume":"25","author":"Chu","year":"2026","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0230","article-title":"Characterization of MAIT cells in glioblastoma reveals a potential immunosuppressive role through a MAIT-neutrophil axis","volume":"7","author":"Keretsu","year":"2025","journal-title":"Neuro-oncol. Adv."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189691_bb0235","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/annonc\/mdy506","article-title":"Evolutionary dynamics of residual disease in human glioblastoma","volume":"30","author":"Spiteri","year":"2019","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189691_bb0240","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/neuonc\/nov119","article-title":"Intratumoral heterogeneity in glioblastoma: don\u2019t forget the peritumoral brain zone","volume":"17","author":"Lemee","year":"2015","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0245","doi-asserted-by":"crossref","first-page":"10885","DOI":"10.1038\/s41467-024-55243-5","article-title":"Turning attention to tumor-host interface and focus on the peritumoral heterogeneity of glioblastoma","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0250","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2026019","article-title":"Spatial immune heterogeneity of hypoxia-induced exhausted features in high-grade glioma","volume":"11","author":"Kim","year":"2022","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189691_bb0255","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Sautes-Fridman","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189691_bb0260","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1016\/j.immuni.2025.09.018","article-title":"Spatial immune profiling defines a subset of human gliomas with functional tertiary lymphoid structures","volume":"58","author":"Cakmak","year":"2025","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0265","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1038\/s41467-021-24347-7","article-title":"Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma","volume":"12","author":"van Hooren","year":"2021","journal-title":"Nat. Commun."},{"issue":"8070","key":"10.1016\/j.bbcan.2026.189691_bb0270","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41586-025-08997-x","article-title":"Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity","volume":"643","author":"Faust Akl","year":"2025","journal-title":"Nature"},{"issue":"8078","key":"10.1016\/j.bbcan.2026.189691_bb0275","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/s41586-025-09191-9","article-title":"Barcoded viral tracing identifies immunosuppressive astrocyte-glioma interactions","volume":"644","author":"Andersen","year":"2025","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189691_bb0280","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1158\/0008-5472.CAN-05-3773","article-title":"Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma","volume":"66","author":"Fecci","year":"2006","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.bbcan.2026.189691_bb0285","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adr6940","article-title":"Immune cell infiltration into brain tumor microenvironment is mediated by Rab27-regulated vascular wall integrity","volume":"11","author":"Adnani","year":"2025","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189691_bb0290","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3171\/jns.2002.96.3.0580","article-title":"Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism","volume":"96","author":"Didenko","year":"2002","journal-title":"J. Neurosurg."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0295","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13045-024-01544-7","article-title":"Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives","volume":"17","author":"Lin","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189691_bb0300","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-23-0913","article-title":"Glioblastoma-infiltrating CD8+ T cells are predominantly a clonally expanded GZMK+ effector population","volume":"14","author":"Wang","year":"2024","journal-title":"Cancer Discov."},{"issue":"7948","key":"10.1016\/j.bbcan.2026.189691_bb0305","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-022-05680-3","article-title":"Single-cell spatial immune landscapes of primary and metastatic brain tumours","volume":"614","author":"Karimi","year":"2023","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189691_bb0310","article-title":"Integrative CSF profiling identifies disease-specific immune responses in leptomeningeal disease","volume":"7","author":"Nieto","year":"2026","journal-title":"Cell Rep Med"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189691_bb0315","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1038\/s41591-024-03152-x","article-title":"Cranioencephalic functional lymphoid units in glioblastoma","volume":"30","author":"Dobersalske","year":"2024","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189691_bb0320","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/s41593-026-02265-5","article-title":"Spatial and single-cell characterization of human glioblastoma tumor microenvironment reveals malignant cellular communities","volume":"29","author":"Lin","year":"2026","journal-title":"Nat. Neurosci."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189691_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2024.03.029","article-title":"Integrative spatial analysis reveals a multi-layered organization of glioblastoma","volume":"187","author":"Greenwald","year":"2024","journal-title":"Cell"},{"issue":"22","key":"10.1016\/j.bbcan.2026.189691_bb0330","doi-asserted-by":"crossref","first-page":"7047","DOI":"10.1158\/1078-0432.CCR-17-0077","article-title":"Tumor resection recruits effector T cells and boosts therapeutic efficacy of encapsulated stem cells expressing IFNbeta in glioblastomas","volume":"23","author":"Choi","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189691_bb0335","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/neuros\/nyz198","article-title":"Radiotherapy, lymphopenia, and host immune capacity in glioblastoma: a potentially actionable toxicity associated with reduced efficacy of radiotherapy","volume":"85","author":"Kleinberg","year":"2019","journal-title":"Neurosurgery"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189691_bb0340","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3109\/07357907.2012.762780","article-title":"The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells","volume":"31","author":"Yovino","year":"2013","journal-title":"Cancer Investig."},{"issue":"13","key":"10.1016\/j.bbcan.2026.189691_bb0345","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20133212","article-title":"Tumor microenvironment as a \u201cgame changer\u201d in cancer radiotherapy","volume":"20","author":"Jarosz-Biej","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0350","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s40425-019-0634-9","article-title":"Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination","volume":"7","author":"Grapin","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0355","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","article-title":"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"2021","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189691_bb0360","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/neuonc\/noac239","article-title":"Exploiting radiation immunostimulatory effects to improve glioblastoma outcome","volume":"25","author":"Awada","year":"2023","journal-title":"Neuro-oncology"},{"key":"10.1016\/j.bbcan.2026.189691_bb0365","article-title":"Immunotherapeutic hydrogel with photothermal induced immunogenic cell death and STING activation for post-surgical treatment","volume":"33","author":"Wang","year":"2023","journal-title":"Adv. Funct. Mater."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189691_bb0370","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202416265","article-title":"Biomimetic dual-driven heterojunction nanomotors for targeted catalytic immunotherapy of glioblastoma","volume":"35","author":"Ye","year":"2025","journal-title":"Adv. Funct. Mater."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189691_bb0375","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ijrobp.2022.08.011","article-title":"Evaluation of the role of the immune system response after minibeam radiation therapy","volume":"115","author":"Bertho","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.bbcan.2026.189691_bb0380","article-title":"A first evaluation of the efficacy of minibeam radiation therapy combined with an immune check point inhibitor in a model of glioma-bearing rats","volume":"51","author":"Iturri","year":"2025","journal-title":"Clin. Transl. Radiat. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189691_bb0385","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41590-022-01215-0","article-title":"Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression","volume":"23","author":"Yeo","year":"2022","journal-title":"Nat. Immunol."},{"issue":"16","key":"10.1016\/j.bbcan.2026.189691_bb0390","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1158\/1078-0432.CCR-11-0774","article-title":"Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide","volume":"17","author":"Grossman","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"8060","key":"10.1016\/j.bbcan.2026.189691_bb0395","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41586-025-08633-8","article-title":"Programs, origins and immunomodulatory functions of myeloid cells in glioma","volume":"640","author":"Miller","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189691_bb0400","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/831090","article-title":"Impact of temozolomide on immune response during malignant glioma chemotherapy","volume":"2012","author":"Sengupta","year":"2012","journal-title":"Clin. Dev. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0405","doi-asserted-by":"crossref","DOI":"10.1093\/oxfimm\/iqad006","article-title":"The current state and future of T-cell exhaustion research","volume":"4","author":"Jenkins","year":"2023","journal-title":"Oxf. Open Immunol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189691_bb0410","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/neuonc\/noq157","article-title":"Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma","volume":"13","author":"Sampson","year":"2010","journal-title":"Neuro-oncology"},{"key":"10.1016\/j.bbcan.2026.189691_bb0415","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1438044","article-title":"Radiation immunodynamics in patients with glioblastoma receiving chemoradiation","volume":"15","author":"Sloan","year":"2024","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189691_bb0420","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202409229","article-title":"A novel multicompartment barrier-free microfluidic device reveals the impact of extracellular matrix stiffening and temozolomide on immune-tumor interactions in glioblastoma","volume":"21","author":"Bayona","year":"2025","journal-title":"Small"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0425","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1039\/D5LC01018G","article-title":"Engineering spatially defined extracellular matrix gradients to govern self-organized multicellular aggregates in a glioblastoma-on-a-chip","volume":"26","author":"Li","year":"2026","journal-title":"Lab Chip"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189691_bb0430","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.ijrobp.2004.12.085","article-title":"Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection","volume":"62","author":"Hughes","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.bbcan.2026.189691_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101474","article-title":"Radiotherapy: an immune response modifier for immuno-oncology","volume":"52","author":"De Martino","year":"2021","journal-title":"Semin. Immunol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189691_bb0440","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41571-019-0177-5","article-title":"Challenges to curing primary brain tumours","volume":"16","author":"Aldape","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.bbcan.2026.189691_bb0445","doi-asserted-by":"crossref","DOI":"10.1172\/JCI169314","article-title":"Immune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors","volume":"133","author":"Sun","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189691_bb0450","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/neuonc\/noz185","article-title":"Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages","volume":"22","author":"de Groot","year":"2020","journal-title":"Neuro-oncology"},{"issue":"7849","key":"10.1016\/j.bbcan.2026.189691_bb0455","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41586-021-03235-6","article-title":"Lipid signalling enforces functional specialization of Treg cells in tumours","volume":"591","author":"Lim","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0460","doi-asserted-by":"crossref","first-page":"10757","DOI":"10.1038\/s41467-024-54326-7","article-title":"Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort","volume":"15","author":"McFaline-Figueroa","year":"2024","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189691_bb0465","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41591-018-0339-5","article-title":"Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma","volume":"25","author":"Schalper","year":"2019","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0470","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.1038\/s41467-021-26940-2","article-title":"Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma","volume":"12","author":"Lee","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0475","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00401-025-02937-9","article-title":"Spatial transcriptomic analysis reveals lack of response to PD-1 blockade in recurrent glioblastoma","volume":"150","author":"Artzi","year":"2025","journal-title":"Acta Neuropathol."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189691_bb0480","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/cncr.33378","article-title":"Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: results from the multicohort phase 1 KEYNOTE-028 trial","volume":"127","author":"Reardon","year":"2021","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0485","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1038\/s41467-019-10493-6","article-title":"Tumor-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma","volume":"10","author":"Henrik Heiland","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0490","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1215\/15228517-2007-035","article-title":"Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma","volume":"10","author":"Mitchell","year":"2007","journal-title":"Neuro-oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189691_bb0495","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1158\/1535-7163.MCT-09-0124","article-title":"An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme","volume":"8","author":"Sampson","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0500","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol."},{"issue":"14 Pt 1","key":"10.1016\/j.bbcan.2026.189691_bb0505","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1158\/1078-0432.CCR-06-0053","article-title":"Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells","volume":"12","author":"Fecci","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189691_bb0510","article-title":"Oncolytic viruses and neoantigen vaccines: opportunities and challenges in priming antitumour immunity","volume":"64","author":"Mansinho","year":"2026","journal-title":"Lancet Reg Health Eur"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189691_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2025.12.055","article-title":"Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial","volume":"189","author":"Meylan","year":"2026","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0520","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31262-y","article-title":"A phase I\/II study of triple-mutated oncolytic herpes virus G47\u2206 in patients with progressive glioblastoma","volume":"13","author":"Todo","year":"2022","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189691_bb0525","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41591-025-03619-5","article-title":"Author correction: Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial","volume":"31","author":"Todo","year":"2025","journal-title":"Nat. Med."},{"issue":"1\u20132","key":"10.1016\/j.bbcan.2026.189691_bb0530","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jneuroim.2013.08.013","article-title":"Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level","volume":"264","author":"Kmiecik","year":"2013","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0535","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1038\/s41467-025-58366-5","article-title":"Combined targeting of glioblastoma stem cells of different cellular states disrupts malignant progression","volume":"16","author":"Lu","year":"2025","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189691_bb0540","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20112746","article-title":"Proneural-mesenchymal transition: phenotypic plasticity to acquire multitherapy resistance in glioblastoma","volume":"20","author":"Fedele","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189691_bb0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.05.007","article-title":"Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells","volume":"181","author":"Klemm","year":"2020","journal-title":"Cell"},{"issue":"17","key":"10.1016\/j.bbcan.2026.189691_bb0550","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1158\/1078-0432.CCR-17-2617","article-title":"Immunophenotyping of newly diagnosed and recurrent glioblastoma defines distinct immune exhaustion profiles in peripheral and tumor-infiltrating lymphocytes","volume":"24","author":"Mohme","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189691_bb0555","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11041219","article-title":"Transcriptional profiling of a patient-matched cohort of glioblastoma (IDH-wildtype) for therapeutic target and repurposing drug identification","volume":"11","author":"Roddy","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbcan.2026.189691_bb0560","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00835","article-title":"Single-cell atlas reveals complexity of the immunosuppressive microenvironment of initial and recurrent glioblastoma","volume":"11","author":"Fu","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2025.11.006","article-title":"Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence","volume":"44","author":"Piyadasa","year":"2025","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189691_bb0570","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.179853","article-title":"Spatial analysis of recurrent glioblastoma reveals perivascular niche organization","volume":"9","author":"Onubogu","year":"2024","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0575","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41392-021-00808-9","article-title":"Correction: both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway","volume":"6","author":"Du","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189691_bb0580","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/s41593-019-0446-8","article-title":"Author correction: control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39","volume":"22","author":"Takenaka","year":"2019","journal-title":"Nat. Neurosci."},{"issue":"552","key":"10.1016\/j.bbcan.2026.189691_bb0585","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw7843","article-title":"Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance","volume":"12","author":"Akkari","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0590","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41467-022-28523-1","article-title":"T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10","volume":"13","author":"Ravi","year":"2022","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189691_bb0595","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1016\/j.cell.2025.03.018","article-title":"A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer","volume":"188","author":"Liu","year":"2025","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189691_bb0600","article-title":"Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis","volume":"3","author":"Yang","year":"2022","journal-title":"Cell Rep Med"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189691_bb0605","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci15080833","article-title":"Unraveling glioblastoma heterogeneity: advancing immunological insights and therapeutic innovations","volume":"15","author":"Liu","year":"2025","journal-title":"Brain Sci."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189691_bb0610","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An integrative model of cellular states, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0615","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1038\/s41467-020-17979-8","article-title":"Author correction: single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy","volume":"11","author":"Couturier","year":"2020","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189691_bb0620","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ccell.2022.05.009","article-title":"Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma","volume":"40","author":"Ravi","year":"2022","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189691_bb0625","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.ccell.2025.05.007","article-title":"Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma","volume":"43","author":"Hara","year":"2025","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0630","article-title":"Spatial architecture of high-grade glioma reveals tumor heterogeneity within distinct domains","volume":"5","author":"Moffet","year":"2023","journal-title":"Neuro-Oncol. Adv."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189691_bb0635","doi-asserted-by":"crossref","DOI":"10.1172\/JCI195556","article-title":"Oligodendrocyte transcription factor 2 orchestrates glioblastoma immune evasion by suppressing CXCL10 and CD8+ T cell activation","volume":"136","author":"Zhang","year":"2026","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189691_bb0640","first-page":"1534","article-title":"A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets","volume":"3","author":"Wang","year":"2022","journal-title":"Nat. Can."},{"key":"10.1016\/j.bbcan.2026.189691_bb0645","article-title":"Molecular and clinicopathological characterization of a prognostic immune gene signature associated with MGMT methylation in glioblastoma","volume":"9","author":"Zhao","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bbcan.2026.189691_bb0650","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1328375","article-title":"Glioblastoma with high O6-methyl-guanine DNA methyltransferase expression are more immunologically active than tumors with low MGMT expression","volume":"15","author":"Kushihara","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0655","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccell.2017.12.012","article-title":"Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment","volume":"33","author":"Wang","year":"2018","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189691_bb0660","doi-asserted-by":"crossref","first-page":"N9","DOI":"10.1227\/NEU.0000000000000580","article-title":"Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma","volume":"75","author":"Zhang","year":"2014","journal-title":"Neurosurgery"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0665","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13059-021-02259-5","article-title":"The evolution of alternative splicing in glioblastoma under therapy","volume":"22","author":"Wang","year":"2021","journal-title":"Genome Biol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0670","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41467-022-28372-y","article-title":"Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target","volume":"13","author":"Abdelfattah","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0675","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.13111","article-title":"Differential expression of checkpoint markers in the normoxic and hypoxic microenvironment of glioblastomas","volume":"33","author":"Petterson","year":"2022","journal-title":"Brain Pathol. (Zurich, Switzerland)"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189691_bb0680","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1158\/1541-7786.MCR-17-0680","article-title":"Microenvironment-derived regulation of HIF signaling drives transcriptional heterogeneity in glioblastoma multiforme","volume":"16","author":"Heiland","year":"2018","journal-title":"Mol. Cancer Res."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189691_bb0685","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25052529","article-title":"Glioblastoma therapy: past, present and future","volume":"25","author":"Obrador","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0690","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1600-065X.2012.01152.x","article-title":"mTOR, metabolism, and the regulation of T-cell differentiation and function","volume":"249","author":"Waickman","year":"2012","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189691_bb0695","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molcel.2010.06.022","article-title":"Activation of a metabolic gene regulatory network downstream of mTOR complex 1","volume":"39","author":"D\u00fcvel","year":"2010","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0700","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189691_bb0705","article-title":"Hypoxia-driven protease legumain promotes immunosuppression in glioblastoma","volume":"4","author":"Pang","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.bbcan.2026.189691_bb0710","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1431112","article-title":"Metabolic adaptation of myeloid cells in the glioblastoma microenvironment","volume":"15","author":"Essakhi","year":"2024","journal-title":"Front. Immunol."},{"issue":"24","key":"10.1016\/j.bbcan.2026.189691_bb0715","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1007\/s00018-020-03569-w","article-title":"Metabolic heterogeneity and adaptability in brain tumors","volume":"77","author":"Badr","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189691_bb0720","doi-asserted-by":"crossref","first-page":"47","DOI":"10.15698\/cst2019.02.176","article-title":"Metabolic and functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in glioblastoma","volume":"3","author":"Won","year":"2019","journal-title":"Cell Stress"},{"issue":"Pt A","key":"10.1016\/j.bbcan.2026.189691_bb0725","article-title":"Indoleamine 2,3-dioxygenase-1 involves in CD8+T cell exhaustion in glioblastoma via regulating tryptophan levels","volume":"142","author":"Zhou","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"22","key":"10.1016\/j.bbcan.2026.189691_bb0730","doi-asserted-by":"crossref","first-page":"6110","DOI":"10.1158\/1078-0432.CCR-12-2130","article-title":"IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival","volume":"18","author":"Wainwright","year":"2012","journal-title":"Clin. Cancer Res. Offl. J. Am. Assoc. Cancer Res."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189691_bb0735","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.cell.2021.03.023","article-title":"Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion","volume":"184","author":"Gangoso","year":"2021","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189691_bb0740","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41556-025-01839-y","article-title":"Inhibiting macrophage-derived lactate transport restores cGAS-STING signalling and enhances antitumour immunity in glioblastoma","volume":"28","author":"Li","year":"2026","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0745","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ccell.2025.11.006","article-title":"Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence","volume":"44","author":"Piyadasa","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189691_bb0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123067","article-title":"Gamma-aminobutyric acid-mediated neuro-immune interactions in glioblastoma: implications for prognosis and immunotherapy response","volume":"357","author":"Sun","year":"2024","journal-title":"Life Sci."},{"issue":"7846","key":"10.1016\/j.bbcan.2026.189691_bb0755","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41586-020-03116-4","article-title":"Gut-licensed IFN\u03b3+ NK cells drive LAMP1+TRAIL+ anti-inflammatory astrocytes","volume":"590","author":"Sanmarco","year":"2021","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189691_bb0760","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26020669","article-title":"The impact of metabolic rewiring in glioblastoma: the immune landscape and therapeutic strategies","volume":"26","author":"Vijayanathan","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189691_bb0765","doi-asserted-by":"crossref","first-page":"1655980","DOI":"10.3389\/fimmu.2025.1655980","article-title":"Thymidine kinase 1 related to Prolif-like T cells promoted GBM through regulation of cell cycle and EMT signals: a comprehensive research based on multi-omics analysis and experimental validation","volume":"16","author":"Deng","year":"2025","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189691_bb0770","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/neuonc\/not067","article-title":"Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas","volume":"15","author":"Xu","year":"2013","journal-title":"Neuro-oncology"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0775","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1038\/s41467-022-32430-w","article-title":"Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma","volume":"13","author":"Coy","year":"2022","journal-title":"Nat. Commun."},{"issue":"16","key":"10.1016\/j.bbcan.2026.189691_bb0780","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1158\/1078-0432.CCR-18-0047","article-title":"T-cell dysfunction in glioblastoma: applying a new framework","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin. Cancer Res. Offl. J. Am. Assoc. Cancer Res."},{"issue":"Pt 3","key":"10.1016\/j.bbcan.2026.189691_bb0785","article-title":"Single-cell and spatial analyses reveal the effect of VSIG4+S100A10+TAMs on the immunosuppression of glioblastoma and anti-PD-1 immunotherapy","volume":"308","author":"Liu","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189691_bb0790","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.04.038","article-title":"Glioma progression is shaped by genetic evolution and microenvironment interactions","volume":"185","author":"Varn","year":"2022","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189691_bb0795","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2007.05.012","article-title":"Comparative analysis of peripheral and localised cytokine secretion in glioblastoma patients","volume":"39","author":"Zisakis","year":"2007","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189691_bb0800","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189691_bb0805","first-page":"449","article-title":"Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features","volume":"28","author":"Sun","year":"2020","journal-title":"J. Xray Sci. Technol."},{"issue":"13","key":"10.1016\/j.bbcan.2026.189691_bb0810","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1245\/s10434-019-07815-9","article-title":"Preoperative radiomic approach to evaluate tumor-infiltrating CD8(+) T cells in hepatocellular carcinoma patients using contrast-enhanced computed tomography","volume":"26","author":"Liao","year":"2019","journal-title":"Ann. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189691_bb0815","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.acra.2019.04.016","article-title":"Assessing PD-L1 expression level by radiomic features from PET\/CT in nonsmall cell lung cancer patients: an initial result","volume":"27","author":"Jiang","year":"2020","journal-title":"Acad. Radiol."},{"issue":"Supplement_7","key":"10.1016\/j.bbcan.2026.189691_bb0820","doi-asserted-by":"crossref","first-page":"vii3","DOI":"10.1093\/neuonc\/noae158.009","article-title":"PRECISE-GBM: a radiogenomic machine learning based study to identify predictive radiomics for evaluation of cancer immune signature in IDHW glioblastoma","volume":"26","author":"Ghimire","year":"2024","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0825","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41698-023-00413-9","article-title":"Radiomics for characterization of the glioma immune microenvironment","volume":"7","author":"Khalili","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.bbcan.2026.189691_bb0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2023.103353","article-title":"MRI histogram analysis of tumor-infiltrating CD8+ T cell levels in patients with glioblastoma","volume":"37","author":"Xue","year":"2023","journal-title":"Neuroimage Clin"},{"key":"10.1016\/j.bbcan.2026.189691_bb0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2024.100985","article-title":"Advancing glioblastoma treatment by targeting metabolism","volume":"51","author":"Zhao","year":"2024","journal-title":"Neoplasia"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189691_bb0840","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41419-024-06697-4","article-title":"Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy","volume":"15","author":"Mai","year":"2024","journal-title":"Cell Death Dis."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189691_bb0845","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1158\/2326-6066.CIR-21-1050","article-title":"Immunologic features in De novo and recurrent glioblastoma are associated with survival outcomes","volume":"10","author":"Alanio","year":"2022","journal-title":"Cancer Immunol. Res."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189691_bb0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.113346","article-title":"Comparative efficacy and safety of therapeutic strategies for EGFRvIII positive recurrent glioblastoma","volume":"28","author":"Qiu","year":"2025","journal-title":"IScience"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189691_bb0855","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0860","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/s41467-025-67415-y","article-title":"Local therapeutic platform prevents postsurgical GBM recurrence by diminishing GICs and reshaping immunosuppressive microenvironment","volume":"17","author":"Zhu","year":"2025","journal-title":"Nat. Commun."},{"issue":"25","key":"10.1016\/j.bbcan.2026.189691_bb0865","doi-asserted-by":"crossref","first-page":"22900","DOI":"10.1021\/acsnano.5c01541","article-title":"NIR-II engineered exosome nanotheranostic probes for \u201coriented blasting\u201d in orthotopic glioblastoma","volume":"19","author":"Yu","year":"2025","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189691_bb0870","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adx9671","article-title":"STING stimulation via supramolecular prodrug hydrogel boosts innate-adaptive immune cross-talk to prevent glioblastoma recurrence","volume":"12","author":"Shang","year":"2026","journal-title":"Sci. Adv."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189691_bb0875","first-page":"665","article-title":"CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma","volume":"4","author":"van Hooren","year":"2023","journal-title":"Nat. Can."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189691_bb0880","first-page":"794","article-title":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","volume":"2","author":"Vanhersecke","year":"2021","journal-title":"Nat. Can."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189691_bb0885","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S1470-2045(23)00347-9","article-title":"Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial","volume":"24","author":"Umemura","year":"2023","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189691_bb0890","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1093\/neuonc\/noaf099","article-title":"Multimodal glioma immunotherapy combining TLR9-targeted STAT3 antisense oligodeoxynucleotides with PD1 immune checkpoint blockade","volume":"27","author":"Hung","year":"2025","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0895","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro-Oncology"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189691_bb0900","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro-Oncology"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189691_bb0905","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyad095","article-title":"Hypofractionated stereotactic re-irradiation and anti-PDL1 durvalumab combination in recurrent glioblastoma: STERIMGLI phase I results","volume":"28","author":"Pouessel","year":"2023","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0910","article-title":"Ipilimumab with temozolomide vs. temozolomide alone after surgery and chemoradiotherapy in recently diagnosed glioblastoma: a randomized phase II clinical trial","volume":"7","author":"Brown","year":"2025","journal-title":"Neurooncol. Adv."},{"issue":"27","key":"10.1016\/j.bbcan.2026.189691_bb0915","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO-25-00618","article-title":"Dual immune check point blockade in MGMT-unmethylated newly diagnosed glioblastoma: NRG oncology BN007, a randomized phase II\/III clinical trial","volume":"43","author":"Lassman","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189691_bb0920","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-20-2500","article-title":"Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma","volume":"27","author":"Nayak","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189691_bb0925","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001146","article-title":"Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)","volume":"8","author":"Awada","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189691_bb0930","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189691_bb0935","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1038\/s41591-025-03895-1","article-title":"Author correction: oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial","volume":"31","author":"Nassiri","year":"2025","journal-title":"Nat. Med."},{"issue":"15_suppl","key":"10.1016\/j.bbcan.2026.189691_bb0940","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS2581","article-title":"Phase II study of pembrolizumab plus SurVaxM for glioblastoma at first recurrence","volume":"38","author":"Ahluwalia","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189691_bb0945","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/neuonc\/noab271","article-title":"Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: an open-label, multi-institutional phase I trial","volume":"24","author":"Chiocca","year":"2022","journal-title":"Neuro-Oncology"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189691_bb0950","article-title":"Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: a phase 2 study","volume":"6","author":"Chen","year":"2025","journal-title":"Med (New York, N.Y.)"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189691_bb0955","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cell.2019.11.036","article-title":"A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity","volume":"180","author":"Jacob","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189691_bb0960","doi-asserted-by":"crossref","DOI":"10.1088\/1758-5090\/ad5764","article-title":"Development of an organ-on-chip model for the detection of volatile organic compounds as potential biomarkers of tumour progression","volume":"16","author":"Bayona","year":"2024","journal-title":"Biofabrication"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:23:26Z","timestamp":1789518206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26001630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":192,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0304419X26001630"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189691","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decoding the spatiotemporal dynamics of T cell immune landscapes in glioblastoma: remodeling precision combination therapies","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189691","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189691"}}